2 results
Approved WMORecruiting
Main study:Primary:Efficacy:- To assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous injection of zalunfiban versusplacebo in STEMI subjects in the pre-hospital setting.Safety:- To assess bleeding events (…
Approved WMORecruiting
Dose escalationPrimary• To determine the RP2D of single-agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or without an anti-VEGF therapy, and with an anti-EGFR therapy (if RASwt)Secondary• To characterize the safety and…